Biosimilar trastuzumab: Phase I data

A European Phase I trial in 118 healthy volunteers showed that Synthon's biosimilar of trastuzumab was bioequivalent to cancer drug Herceptin trastuzumab. Details were not disclosed. Synthon said it i...